We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+2.52%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$7.16B
AUM Growth
+$666M
(+10%)
Cap. Flow
+$831M
Cap. Flow
% of AUM
11.61%
Top 10 Holdings %
Top 10 Hldgs %
17.05%
Holding
983
New
189
Increased
207
Reduced
145
Closed
240
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$146M |
| 2 |
Gilead Sciences
GILD
|
+$116M |
| 3 |
Amazon
AMZN
|
+$86.4M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$84.7M |
| 5 |
Analog Devices
ADI
|
+$80M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$73.2M |
| 2 |
Palo Alto Networks
PANW
|
+$59.8M |
| 3 |
Alkermes
ALKS
|
+$55.3M |
| 4 |
Accenture
ACN
|
+$53.8M |
| 5 |
Johnson & Johnson
JNJ
|
+$53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.05% |
| 2 | Technology | 29.2% |
| 3 | Financials | 8.76% |
| 4 | Industrials | 7.7% |
| 5 | Communication Services | 4.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NUVA
151
DELISTED
NuVasive, Inc.
NUVA
| $14M | 0.2% |
320,151
-344,859
| -52% | -$16.7M |
|
152
Qualcomm
QCOM
$169B
| $13.9M | 0.19% |
+123,396
| New | +$17M |
|
|
CCXI
153
DELISTED
ChemoCentryx, Inc.
CCXI
| $13.8M | 0.19% |
+267,540
| New | +$11.1M |
|
154
SkinHealth Systems
SKIN
$96M
| $13.7M | 0.19% |
1,164,369
+2
| +0% | +$25 |
|
155
Denali Therapeutics
DNLI
$3.76B
| $13.6M | 0.19% |
444,256
+263,284
| +145% | +$8.56M |
|
|
ITCI
156
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $13.4M | 0.19% |
288,326
+160,984
| +126% | +$8.41M |
|
157
Colgate-Palmolive
CL
$72.2B
| $13.4M | 0.19% |
190,666
-232,820
| -55% | -$18.3M |
|
158
Dollar Tree
DLTR
$25B
| $13.3M | 0.19% |
+97,712
| New | +$15.2M |
|
|
ACDI
159
DELISTED
Ascendant Digital Acquisition Corp. III
ACDI
| $13M | 0.18% |
1,286,000
-226,900
| -15% | -$2.29M |
|
160
Arcturus Therapeutics
ARCT
$171M
| $13M | 0.18% |
+877,524
| New | +$14.7M |
|
161
Altimmune
ALT
$581M
| $13M | 0.18% |
1,018,091
+467,406
| +85% | +$6.9M |
|
162
Dollar General
DG
$28B
| $12.9M | 0.18% |
53,903
-30,555
| -36% | -$7.54M |
|
163
Keros Therapeutics
KROS
$205M
| $12.9M | 0.18% |
+342,493
| New | +$11.9M |
|
|
VERV
164
DELISTED
Verve Therapeutics
VERV
| $12.9M | 0.18% |
374,995
+224,995
| +150% | +$7.18M |
|
165
Guidewire Software
GWRE
$13.3B
| $12.8M | 0.18% |
207,956
-27,310
| -12% | -$1.97M |
|
|
MGI
166
DELISTED
MoneyGram International, Inc. New
MGI
| $12.6M | 0.18% |
1,215,632
+75,629
| +7% | +$779K |
|
167
RTX Corp
RTX
$291B
| $12.5M | 0.17% |
+152,696
| New | +$13.8M |
|
|
VISN
168
Vistance Networks Inc
VISN
$2.81B
| $12.4M | 0.17% |
+1,342,491
| New | +$12.9M |
|
169
Lattice Semiconductor
LSCC
$19.1B
| $12.4M | 0.17% |
251,232
+46,412
| +23% | +$2.57M |
|
|
BKI
170
DELISTED
Black Knight, Inc. Common Stock
BKI
| $12.4M | 0.17% |
+191,000
| New | +$12.6M |
|
|
BTRS
171
DELISTED
BTRS Holdings Inc. Class 1 Common Stock
BTRS
| $12.3M | 0.17% |
+1,330,312
| New | +$8.62M |
|
172
ICU Medical
ICUI
$4.25B
| $12.3M | 0.17% |
81,613
+74,333
| +1,021% | +$12.4M |
|
173
Micron Technology
MU
$1T
| $12.2M | 0.17% |
243,920
-252,922
| -51% | -$14.7M |
|
174
Howmet Aerospace
HWM
$115B
| $12.1M | 0.17% |
+390,291
| New | +$13.7M |
|
|
APGB
175
DELISTED
Apollo Strategic Growth Capital II
APGB
| $12M | 0.17% |
1,219,075
+919,075
| +306% | +$9.05M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2022 Portfolio in Review
As of Q3 2022, Woodline Partners held 983 positions worth $7.16B, up 10% from $6.49B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Woodline Partners deployed $831M of net new capital in Q3 2022, opening 189 new positions and adding to 207 existing holdings. Its largest new stake was Amazon: 683,398 shares worth $77.2M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $73.2M trimmed.
- Woodline Partners's largest Q3 2022 buy was Amazon: 683,398 shares worth $77.2M.
- Woodline Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, an estimated $146M increase.
- Woodline Partners's biggest Q3 2022 reduction was Eli Lilly, cutting an estimated $73.2M.
- Woodline Partners fully exited Palo Alto Networks in Q3 2022, selling an estimated $59.8M.
- Woodline Partners's ten largest holdings make up 17% of its $7.16B portfolio in Q3 2022.
- Woodline Partners opened 189 new positions and closed 240 in Q3 2022.
- Woodline Partners's portfolio value rose 10% quarter-over-quarter to $7.16B.
Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.